BRIDGenomics

BRIDGenomics is a precision medicine company specializing in high-sensitivity genomic testing for oncology. Based in San Jose, California, the company utilizes its proprietary BRIDG platform to perform liquid biopsy and next-generation sequencing (NGS) for the detection of circulating tumor DNA (ctDNA). Their diagnostic solutions, including the BRIDG-Lung and BRIDG-Pan panels, are designed to identify actionable mutations and guide personalized treatment strategies for cancer patients. By providing real-time molecular profiling, BRIDGenomics enables clinicians to monitor treatment response and detect minimal residual disease (MRD) earlier than traditional imaging. The company's mission is to bridge the gap between complex genomic data and clinical decision-making to improve patient outcomes.